 HC Wainwright downgraded Humanigen Inc NASDAQ: HGEN to Neutral from Buy and removed the price target based on the removal of COVID-19 from lenzilumab projections and the lack of near-term catalysts beyond COVID-19 that could potentially drive the shares. The analyst looks to. 